Press Release
HUTCHMED Highlights Data to be Presented at AACR
Congress 2024
Hong Kong, Shanghai
& Florham Park, NJ - Friday, April 5,
2024: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM;
HKEX:13) today announces that new and updated data from several
studies of compounds discovered by HUTCHMED will be presented at
the upcoming American Association of Cancer Research ("AACR")
Annual Meeting 2024, taking place on April 5-10, 2024 in San Diego,
California.
Initial preclinical data will be presented for
HMPL-506, a novel, highly potent and differentiated
menin-MLL inhibitor for the treatment of certain types of
acute leukemia. Compared with five other menin inhibitors in
clinical development, HMPL-506 showed the stronger inhibitory
potency in MLL-rearranged
and NPM1 mutant leukemia
cell line models. Furthermore, HMPL-506 in combination with
azacytidine, venetoclax or gilteritinib synergistically improved
the anti-tumor effect against MLL-rearranged leukemias both
in vitro and in vivo. The investigational drug
candidate displayed favorable pharmacokinetic profiles, high
selectivity and low risk of cardiac toxicity. A Phase I study
of HMPL-506 is planned for the second half of 2024.
Initial preclinical data will also be presented for
HMPL-A067 (HMA800067), a novel
CD38-targeting antibody-drug conjugate (ADC) in which
daratumumab was conjugated with cytotoxic payload Monomethyl
auristatin E (MMAE) via a novel linker. It demonstrated significant
superior anti-tumor activity to daratumumab, including in
several B-cell malignancies models with resistance to daratumumab
treatment.
Other presentations include preclinical data on the
ERK 1/2 inhibitor, HMPL-295; early clinical data on the
Syk inhibitor, sovleplenib,
in lymphoma patients; additional clinical data from global studies
of VEGFR inhibitor, fruquintinib, and MET inhibitor,
savolitinib; and several
investigator-initiated studies of fruquintinib and
VEGFR/CSF-1R/FGFR inhibitor, surufatinib.
Details of the presentations are as follows:
Abstract
title
|
Presenter / Lead
author
|
Presentation
details
|
SPONSORED STUDIES
|
HMPL-506, a novel, highly potent and differentiated menin-MLL
inhibitor for the treatment of MLL-rearranged
and NPM1mutant acute leukemia in
preclinical models
|
Min Cheng, HUTCHMED, Shanghai, China
|
#2113
Poster Session (PO.ET07.02 -
Pharmacodynamic Biomarkers of Drug Response)
Monday, April 8,
2024
|
HMPL-A067 (HMA800067), a novel CD38-targeting antibody-drug
conjugate (ADC), demonstrated superior anti-tumor activity to
daratumumab in preclinical B-cell malignancies
models
|
Yan Xu,
HUTCHMED, Shanghai, China
|
#1890
Poster Session (PO.ET01.02 -
Antibody-Drug Conjugates and Bispectific Antibodies)
Monday, April 8,
2024
|
Preclinical characterization of HMPL-295, a potent and
selective ERK1/2 inhibitor
|
Jia Hu, HUTCHMED, Shanghai, China
|
#1661
Poster Session (PO.MCB03.01 - Cell
Signaling Components as Therapeutic Targets)
Monday, April 8,
2024
|
Targeting YAP1/TEAD signaling re-sensitizes MAPK/ERK pathway
inhibitors in KRAS-driven cancer cells
|
Xianwen Yang, HUTCHMED, Shanghai, China
|
#1931
Poster Session (PO.ET03.04 - Drug
Resistance 2: Ras GTPase)
Monday, April 8,
2024
|
Safety and Efficacy of Sovleplenib (HMPL-523), a Syk
Inhibitor, in Patients with Relapsed or Refractory
Lymphoma
|
Paolo Strati, The University of
Texas MD Anderson Cancer Center, USA
|
#CT144
Poster Session (PO.CT01.03 - Phase 0 and Phase I Clinical Trials)
Monday, April 8,
2024
|
Early carcinoembryonic antigen (CEA) dynamics to predict the
efficacy of fruquintinib (F) + best supportive care (BSC) in
patients with metastatic colorectal cancer (mCRC) enrolled in
FRESCO-2
|
Stefano Lonardi, Veneto Institute of Oncology IOV-IRCCS Padua,
Italy
|
#6408
Poster Session (PO.CL01.10 -
Predictive Biomarkers 5)
Tuesday, April 9, 2024
|
Savolitinib (savo) + osimertinib (osi) vs savo + placebo (PBO)
in patients (pts) with EGFR-mutated (EGFRm), MET-amplified advanced
NSCLC with progression on osi
|
James Chih-Hsin Yang, National
Taiwan University Hospital and National Taiwan University Cancer
Centre, Taipei, Taiwan
|
#CT251
Poster Session (PO.CL01.10 -
Predictive Biomarkers 5)
Tuesday, April 9, 2024
|
|
|
|
INVESTIGATOR-INITIATED STUDIES
|
Enhanced anticancer efficacy via ROS-dependent ferroptosis:
synergy between surufatinib and cisplatin in small cell lung
cancer
|
Xiaolin Li,
First Affiliated Hospital of Nanjing Medical University, Nanjing,
China
|
#2122
Poster Session (PO.ET07.02 -
Pharmacodynamic Biomarkers of Drug Response)
Monday, April 8,
2024
|
Efficacy and underlying mechanisms of surufatinib in non-small
cell lung cancer treatment
|
Yanfang Zheng, Affiliated Cancer Hospital & Institute of Guangzhou
Medical University, Guangzhou, China
|
#2126
Poster Session (PO.ET07.02 -
Pharmacodynamic Biomarkers of Drug Response)
Monday, April 8,
2024
|
Enhancing Radiosensitivity in Biliary Tract Cancer: The Dual
Role of Surufatinib in Tumor Suppression and Macrophage
Reprogramming
|
Hong Ma, Wuhan Union Hospital, Wuhan,
China
|
#2127
Poster Session (PO.ET07.02 -
Pharmacodynamic Biomarkers of Drug Response)
Monday, April 8,
2024
|
Surufatinib treatment in pancreatic cancer: unveiling the role
of GPR34 in TAMs and enhancing immunotherapy
efficacy
|
Jihui Hao / Song Gao, Tianjin
Medical University Cancer Institute and Hospital, Tianjin,
China
|
#2128
Poster Session (PO.ET07.02 -
Pharmacodynamic Biomarkers of Drug Response)
Monday, April 8,
2024
|
Efficacy and Underlying Mechanisms of Surufatinib Combined
with PD-1 Monoclonal Antibody and Chemotherapy in Pancreatic
Cancer
|
Guanghai Dai / Ru Jia, Chinese
PLA General Hospital (CPLAGH), Beijing, China
|
#2129
Poster Session (PO.ET07.02 -
Pharmacodynamic Biomarkers of Drug Response)
Monday, April 8,
2024
|
Optimizing the treatment schedule of radiotherapy combined
with VEGFR-TKIs and PD-(L) 1 inhibitors in metastatic colorectal
cancer
|
Tao Zhang / Zhenyu Lin, Cancer Center, Union
Hospital Tongji Medical College,
Huazhong University of Science and Technology,
Wuhan, China
|
#3827
Poster Session (PO.CL10.04 - Outcome
Investigation with Real World Data)
Monday, April 8,
2024
|
Clinical and epidemiological profile of neuroendocrine
differentiation- A hospital-based retrospective
study
|
Susheng Shi /
Yaru Wen, Cancer Hospital
Chinese Academy of Medical Sciences, Beijing, China
|
#4630
Poster Session (PO.ET06.04 -
Molecular Classification of Tumors for Diagnostics, Prognostics,
and Therapeutic Outcomes)
Tuesday, April 9, 2024
|
Epidemiological characteristics and treatment strategies of
gastric cancer with neuroendocrine differentiation
(NED)
|
Jun Zhang, The First Affiliated Hospital of
Chongqing Medical University, Chongqing, China
|
#4864
Poster Session (PO.PS01.08 -
Descriptive Epidemiology and Statistical and Epidemiological
Methodology)
Tuesday, April 9, 2024
|
Initial efficacy of surufatinib plus sintilimab and IBI310 for
patients with high-grade advanced-neuroendocrine neoplasm: A
multicenter, single arm phase 2 study
|
Lin Shen / Ming Lu, Peking
University Cancer Hospital and Institute, Beijing, China
|
#CT266
Poster Session (PO.CT02.02 -
Phase II Clinical Trials 2)
Tuesday, April 9, 2024
|
About HUTCHMED
HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative,
commercial-stage, biopharmaceutical company. It is committed to the
discovery, global development and commercialization of targeted
therapies and immunotherapies for the treatment of cancer and
immunological diseases. It has approximately 5,000 personnel across
all its companies, at the center of which is a team of about 1,800
in oncology/immunology. Since inception, HUTCHMED has focused on
bringing cancer drug candidates from in-house discovery to patients
around the world, with its first three medicines marketed in China,
the first of which is also marketed in the U.S. For more
information, please visit: www.hutch-med.com or follow us on
LinkedIn.
Forward-Looking
Statements
This press release contains forward-looking
statements within the meaning of the "safe harbor" provisions of
the U.S. Private Securities Litigation Reform Act of 1995. These
forward-looking statements reflect HUTCHMED's current expectations
regarding future events, including but not limited to its
expectations regarding the therapeutic potential of fruquintinib,
savolitinib, surufatinib, sovleplenib, HMPL-295, HMPL-506 and
HMA800067, the further clinical development for fruquintinib,
savolitinib, surufatinib, sovleplenib, HMPL-295, HMPL-506 and
HMA800067, its expectations as to whether any studies on
fruquintinib, savolitinib, surufatinib, sovleplenib, HMPL-295,
HMPL-506 and HMA800067 would meet their primary or secondary
endpoints, and its expectations as to the timing of the completion
and the release of results from such studies. Such risks and
uncertainties include, among other things, assumptions regarding
enrollment rates and the timing and availability of subjects
meeting a study's inclusion and exclusion criteria; changes to
clinical protocols or regulatory requirements; unexpected adverse
events or safety issues; the ability of fruquintinib, savolitinib,
surufatinib, sovleplenib, HMPL-295, HMPL-506 and HMA800067,
including as combination therapies, to meet the primary or
secondary endpoint of a study, to obtain regulatory approval in
different jurisdictions and to gain commercial acceptance after
obtaining regulatory approval; the potential markets of
fruquintinib, savolitinib, surufatinib, sovleplenib, HMPL-295,
HMPL-506 and HMA800067 for a targeted indication, and the
sufficiency of funding. In addition, as certain studies rely on the
use of nab-paclitaxel, sintilimab, toripalimab, pemetrexed,
platinum, etoposide or cisplatin as combination therapeutics, such
risks and uncertainties include assumptions regarding their safety,
efficacy, supply and continued regulatory approval. Existing and
prospective investors are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof. For further discussion of these and other risks, see
HUTCHMED's filings with the U.S. Securities and Exchange
Commission, The Stock Exchange of Hong Kong Limited and on AIM.
HUTCHMED undertakes no obligation to update or revise the
information contained in this press release, whether as a result of
new information, future events or circumstances or otherwise.
Medical Information
This press release contains information about
products that may not be available in all countries, or may be
available under different trademarks, for different indications, in
different dosages, or in different strengths. Nothing contained
herein should be considered a solicitation, promotion or
advertisement for any prescription drugs including the ones under
development.
CONTACTS
Investor Enquiries
|
+852 2121 8200 /
ir@hutch-med.com
|
|
|
Media Enquiries
|
|
Ben Atwell / Alex Shaw,
FTI Consulting
|
+44 20 3727 1030 /
+44 7771 913 902 (Mobile) /
+44 7779 545 055 (Mobile) / HUTCHMED@fticonsulting.com
|
Zhou Yi, Brunswick
|
+852 9783 6894 (Mobile) /
HUTCHMED@brunswickgroup.com
|
|
|
Nominated Advisor
|
|
Atholl Tweedie /
Freddy Crossley / Daphne Zhang,
Panmure Gordon
|
+44 (20) 7886 2500
|